EUVIMEDEUVIMED entdecken
Crossref

Celastrol-Ligustrazine compound proven to be a novel drug candidate for idiopathic pulmonary fibrosis by intervening in the TGF-β1 mediated pathways-an experimental in vitro and vivo study

Lu Gao, Ying Bai, Chao Liang, Tao Han, Yafeng Liu, Jiawei Zhou, Jianqiang Guo, Jing Wu, Dong Hu

Molecular Diversity · 2025

DOI: 10.1007/s11030-024-10970-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Lu Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Anhui University of Science and Technology, Huainan, Anhui, China. Hauptthemen laut MEDLINE: Pyrazines, Idiopathic Pulmonary Fibrosis, Transforming Growth Factor beta1, Triterpenes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic Pulmonary Fibrosis (IPF) is a disease characterized by pulmonary interstitial fibrosis and collagen proliferation, currently lacking effective therapeutic options. The combined use of Celastrol and Ligustrazine has been proved to synergistically improve the pathological processes of inflammation and fibrosis. In earlier studies, we designed and synthesized a Celastrol-Ligustrazine compound CL-001, though its role in IPF remains unclear. Here, the effects and mechanisms of CL-001 in bleomycin (BLM)-induced IPF were investigated. In vivo, CL-001 significantly improved lung function, reduced pulmonary inflammation, and decreased collagen deposition, thereby preventing the progression of IPF. In vitro, CL-001 concurrently inhibited both Smad-dependent and Smad-independent pathways, thereby suppressing TGF-β1-induced epithelial-mesenchymal transition (EMT) and epithelial cell migration. This inhibitory effect was superior to that of Celastrol or Ligustrazine administered alone. Additionally, CL-001 significantly increased the level of apoptosis and promoted the expression of apoptosis-related proteins (Caspase-8 and PARP), ultimately leading to widespread apoptosis in activated lung epithelial cells. In summary, CL-001 exhibits excellent anti-IPF effects both in vitro and in vivo, suggesting its potential as a novel candidate drug for IPF, warranting further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazinesIdiopathic Pulmonary FibrosisTransforming Growth Factor beta1TriterpenesSignal TransductionPentacyclic TriterpenesAnimalsHumansBleomycinEpithelial-Mesenchymal TransitionApoptosisMiceMaleCell MovementLungCell Line

Stichwörter der Autor:innen

Alveolar epithelial cellCelastrol-Ligustrazine compoundEMTIdiopathic pulmonary fibrosisReactive oxygen species

Substanzen

celastrolPentacyclic TriterpenesPyrazinestetramethylpyrazineTransforming Growth Factor beta1BleomycinTriterpenes

Autor:innen und Institutionen

  • School of Medicine, Anhui University of Science and Technology, Huainan, Anhui, China.
  • Anhui Occupational Health and Safety Engineering Laboratory, Huainan, Anhui, China.
  • School of Medicine, Anhui University of Science and Technology, Huainan, Anhui, China. by0319_cpu@163.com.
  • Anhui Occupational Health and Safety Engineering Laboratory, Huainan, Anhui, China. by0319_cpu@163.com.
  • School of Medicine, Anhui University of Science and Technology, Huainan, Anhui, China. wujing8008@126.com.
  • Anhui Occupational Health and Safety Engineering Laboratory, Huainan, Anhui, China. wujing8008@126.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Gao, L., Bai, Y., Liang, C., Han, T., Liu, Y., Zhou, J., Guo, J., Wu, J., & Hu, D. (2025). Celastrol-Ligustrazine compound proven to be a novel drug candidate for idiopathic pulmonary fibrosis by intervening in the TGF-β1 mediated pathways-an experimental in vitro and vivo study. Molecular Diversity. https://doi.org/10.1007/s11030-024-10970-1

Vancouver

Gao L, Bai Y, Liang C, Han T, Liu Y, Zhou J, et al. Celastrol-Ligustrazine compound proven to be a novel drug candidate for idiopathic pulmonary fibrosis by intervening in the TGF-β1 mediated pathways-an experimental in vitro and vivo study. Molecular Diversity. 2025. doi:10.1007/s11030-024-10970-1

BibTeX
@article{Gao2025,
  author = {Gao, Lu and Bai, Ying and Liang, Chao and Han, Tao and Liu, Yafeng and Zhou, Jiawei and Guo, Jianqiang and Wu, Jing and Hu, Dong},
  title = {Celastrol-Ligustrazine compound proven to be a novel drug candidate for idiopathic pulmonary fibrosis by intervening in the TGF-β1 mediated pathways-an experimental in vitro and vivo study},
  journal = {Molecular Diversity},
  year = {2025},
  doi = {10.1007/s11030-024-10970-1}
}
Kostenlos starten →